Eli Lilly, the manufacturer of the injectable weight-loss medication Zepbound, has its own oral GLP-1 drug in the pipeline, orforglipron, which is being investigated as a treatment for both type 2 diabetes and obesity
In contrast, bariatric surgery provides a more definitive and effective solution for those struggling with obesity and related health issues
It supports strength, balance, mobility, posture, insulin sensitivity, glucose handling, and metabolic resilience
Overall prescribing rates (GLP-1 RA prescriptions as a proportion of all prescriptions) increased by more than one percentage point from December 2025 to March 2026 (+15.0%), representing the largest quarter-over-quarter percentage point increase observed since the start of the study period in 2019
This meant that even if a Part D plan wanted to cover a weight loss drug, it could not legally do so
Source of reviews and verification methodology not disclosed in publicly available documentation